INTRODUCTION
The biotechnology industry is at a critical crossroads, where historical
relationships are being replaced by new business models and technological
innovations. The need to generate profitable supply chains could be fulfilled by
the introduction of new tools and services in the genomics area. Datamonitor has
identified three areas that could impact the evolution of Biomedicine in the
21st century - bioinformatics, population/functional genomics and genomics
tools.
SCOPE OF THIS REPORT
- Analysis of the current state of the bioinformatics, population/functional
genomics and genomics tools markets
- Case studies of Gene Logic, deCODE Genetics and Affymetrix, covering
strategy, alliance networking, technological evolution and financial
performance
- Risk and return related assessment of each company
REPORT HIGHLIGHTS
There is an increasing interest in the pharma and biotech sectors for
licensing new datamining and bioanalytical tools that will be able to support
the drug discovery process and enrich therapeutic pipelines with drug leads and
targets in record time
R&D expenditure in the target discovery process is a critical economical
factor, which the pharma/biotech sector cannot ignore
In the long term, the new leaders in bioinformatics, genomics and genomics
tools, such as Gene Logic, deCODE and Affymetrix, will play a significant role
in the development of the biotech and pharma pipelines. However, in the short
term their business models will continue to be heavily dependent on royalty
payments and data subscriptions
KEY REASONS TO BUY THIS REPORT
- Gain access to an industry assessment of Bioinformatics, Population
Genomics and Genomic Tools
- Evaluate three key players- what is their positioning in terms of
financials, alliance networking and strategic development?
- Assess the high risk and high return potential for each of these players
View Cart
